Printer Friendly

Phylogeny, Inc. Announces Its New microRNA in Situ Hybridization Detection Service.

COLUMBUS, Ohio -- Phylogeny, Inc., the in situ company, announces its new microRNA in situ hybridization detection service.

As scientists investigate the role of regulatory RNA molecules in the development of disease, they will need to move beyond standard whole tissue expression profiling to a more precise method of identifying the exact cells that are modulated by these molecules. Responding to that need, Phylogeny is pleased to announce that it has launched a new in situ service to localize microRNAs (miRNA), one of the fastest-growing areas in biomedical research.

miRNAs regulate gene expression by interacting with messenger RNAs. It is by this mechanism that miRNAs participate in many key biological processes including cellular proliferation, embryonic development, and immunity. The in situ miRNA hybridization method offers sensitive detection of miRNAs in specific cell(s). This allows researchers to study the disruption of miRNAs which are thought to play a critical role in many diseases, including most cancers.

Expanding on their suite of contract research, Phylogeny is the only company offering miRNA in situ detection service. "We are happy to collaborate with our clients and provide them with the expertise to localize and interpret miRNA expression in specific cell populations. Such information will significantly advance the understanding of the biology of miRNAs," said Dr. Adel Mikhail, CEO of Phylogeny, Inc. "Equally important is that this service allows for the detection of miRNA in formalin fixed paraffin embedded (FFPE) tissue thus opening the vast collections of archival FFPE tissue for miRNA research."

Phylogeny is currently accepting a limited number of studies. For further information, please contact a Phylogeny scientist at (614) 436-4917 or

About Phylogeny:

Phylogeny Inc., the in situ company, a CRO established in 1997, serves the research community as experts in design, implementation, and interpretation of studies aimed at elucidating molecular basis of both disease and fundamental biological processes.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 18, 2008
Previous Article:ERF Wireless Launches Aggressive Acquisition Initiative.
Next Article:An Affiliate of Sun Capital Partners, Inc. Acquires Gordmans, a Full-Line, Value-Priced Retailer with 65 Stores in 16 Midwestern States.

Related Articles
BioGenex awarded United States patent on the synthesis of branched oligomers for nucleic acid labeling and amplification.
Vysis obtains multiple genomic target detection patent.
Association between Epstein-Barr virus and classic Hodgkin lymphoma in Jordan: a comparative study with Epstein-Barr virus-associated Hodgkin...
Multiple myeloma; methods and protocols.
In Situ Hybridization Protocols, 3d ed.
MicroRNA Protocols.
Protocols for nucleic acid analysis by nonradioactive probes; 2d ed.
PRINS and PNA technologies in chromosomal investigation. (CD-ROM included).
Rosetta selects PCR as platform for its microRNA-based diagnostics to be launched in 2008.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters